An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Trial Profile

An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Carotuximab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 According to a Tracon Pharmaceuticals media release, company expects to report initial data in the first half of 2018.
    • 18 May 2016 According to a Tracon Pharmaceuticals media release, dosing has been initiated in this trial and topline data are anticipated in 2017.
    • 11 May 2016 According to a TRACON Pharmaceuticals media release, the company expects to initiate dosing in this trial in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top